Friday, January 31, 2025

AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%

Must read




AbbVie’s earnings topped estimates, and it offered an upbeat view of 2025.

Admin (8)

More articles

Latest article